Literature DB >> 1850957

Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas.

C Pyke1, P Kristensen, E Ralfkiaer, J Grøndahl-Hansen, J Eriksen, F Blasi, K Danø.   

Abstract

In this study in situ hybridization methods were used to examine biopsy samples from 13 adenocarcinomas of the colon for the presence of mRNA for the urokinase-type plasminogen activator (u-PA) and its specific cell-surface receptor (u-PAR). In all cases, u-PA mRNA was present in fibroblastlike cells in the stroma adjacent to the invasive tumor nodules. Urokinase-type plasminogen activator mRNA was not detected in the malignant cells. All specimens also contained u-PAR mRNA in cells located at the tumoral-stromal interface of invasive foci, but in contrast at least some of these cells were in all but one case identified as being of malignant origin. Stromal cells, probably tumor-infiltrating macrophages and neutrophils, also were positive in these areas. These results support the view that components of the plasminogen activation system may act to influence proteolytic events occurring at the interface between stroma and malignant cells in adenocarcinomas of the colon in humans.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1850957      PMCID: PMC1886028     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  40 in total

1.  A 55,000-60,000 Mr receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification.

Authors:  L S Nielsen; G M Kellerman; N Behrendt; R Picone; K Danø; F Blasi
Journal:  J Biol Chem       Date:  1988-02-15       Impact factor: 5.157

2.  Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer.

Authors:  M J Duffy; D Reilly; C O'Sullivan; N O'Higgins; J J Fennelly; P Andreasen
Journal:  Cancer Res       Date:  1990-11-01       Impact factor: 12.701

3.  Plasminogen activators in experimental colorectal neoplasia: a role in the adenoma-carcinoma sequence?

Authors:  J S Gelister; M R Lewin; H E Driver; F Savage; M Mahmoud; P J Gaffney; P B Boulos
Journal:  Gut       Date:  1987-07       Impact factor: 23.059

4.  Urokinase-type plasminogen activator in endothelial cells during acute inflammation of the appendix.

Authors:  J Grøndahl-Hansen; L T Kirkeby; E Ralfkiaer; P Kristensen; L R Lund; K Danø
Journal:  Am J Pathol       Date:  1989-10       Impact factor: 4.307

5.  Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans.

Authors:  J Grøndahl-Hansen; E Ralfkiaer; L T Kirkeby; P Kristensen; L R Lund; K Danø
Journal:  Am J Pathol       Date:  1991-01       Impact factor: 4.307

6.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

Review 7.  Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors.

Authors:  F Blasi; J D Vassalli; K Danø
Journal:  J Cell Biol       Date:  1987-04       Impact factor: 10.539

8.  Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants.

Authors:  R W Stephens; J Pöllänen; H Tapiovaara; K C Leung; P S Sim; E M Salonen; E Rønne; N Behrendt; K Danø; A Vaheri
Journal:  J Cell Biol       Date:  1989-05       Impact factor: 10.539

9.  Autocrine activities of basic fibroblast growth factor: regulation of endothelial cell movement, plasminogen activator synthesis, and DNA synthesis.

Authors:  Y Sato; D B Rifkin
Journal:  J Cell Biol       Date:  1988-09       Impact factor: 10.539

10.  Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts.

Authors:  J Pöllänen; K Hedman; L S Nielsen; K Danø; A Vaheri
Journal:  J Cell Biol       Date:  1988-01       Impact factor: 10.539

View more
  98 in total

1.  Thrombospondin-1 and transforming growth factor beta-1 upregulate plasminogen activator inhibitor type 1 in pancreatic cancer.

Authors:  D Albo; D H Berger; J Vogel; G P Tuszynski
Journal:  J Gastrointest Surg       Date:  1999 Jul-Aug       Impact factor: 3.452

2.  Expression of urokinase-type plasminogen activator, stromelysin 1, stromelysin 3, and matrilysin genes in lung carcinomas.

Authors:  I Bolon; M Devouassoux; C Robert; D Moro; C Brambilla; E Brambilla
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

3.  Targeting zymogen activation to control the matriptase-prostasin proteolytic cascade.

Authors:  Zhenghong Xu; Ya-Wen Chen; Aruna Battu; Paul Wilder; David Weber; Wenbo Yu; Alexander D Mackerell; Li-Mei Chen; Karl X Chai; Michael D Johnson; Chen-Yong Lin
Journal:  J Med Chem       Date:  2011-10-12       Impact factor: 7.446

Review 4.  The plasminogen activator/plasmin system.

Authors:  J D Vassalli; A P Sappino; D Belin
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

Review 5.  The matrix metalloproteinases and their inhibitors in pancreatic cancer. From molecular science to a clinical application.

Authors:  S R Bramhall
Journal:  Int J Pancreatol       Date:  1997-02

6.  Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression.

Authors:  T J de Vries; P H Quax; M Denijn; K N Verrijp; J H Verheijen; H W Verspaget; U H Weidle; D J Ruiter; G N van Muijen
Journal:  Am J Pathol       Date:  1994-01       Impact factor: 4.307

7.  Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumour promoters in the human lung carcinoma cell line A549.

Authors:  L R Lund; V Ellis; E Rønne; C Pyke; K Danø
Journal:  Biochem J       Date:  1995-08-15       Impact factor: 3.857

8.  Urokinase type plasminogen activator receptor expression in colorectal neoplasms.

Authors:  S Suzuki; Y Hayashi; Y Wang; T Nakamura; Y Morita; K Kawasaki; K Ohta; N Aoyama; S R Kim; H Itoh; Y Kuroda; W F Doe
Journal:  Gut       Date:  1998-12       Impact factor: 23.059

9.  Urokinase and the intestinal mucosa: evidence for a role in epithelial cell turnover.

Authors:  P R Gibson; I Birchall; O Rosella; V Albert; C F Finch; D H Barkla; G P Young
Journal:  Gut       Date:  1998-11       Impact factor: 23.059

Review 10.  Tumor stroma as targets for cancer therapy.

Authors:  Jing Zhang; Jinsong Liu
Journal:  Pharmacol Ther       Date:  2012-10-12       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.